Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly.

J Endocr Soc · 2021 · PMC7853172 · PMID 33553983

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

showed a trendP = .049actually significant

Compared with matched healthy subjects, IHL showed a trend to be lower in acromegaly patients prepegvisomant, 1.75% (0.7-5%), than in controls, 3.04% (1.57-13.2%) ( P = .049), but did not differ in the patients on pegvisomant, 3.5%, from controls, 3.04% ( P = .85).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.